Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping
Public ClinicalTrials.gov record NCT06244082. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Open-label Study to Evaluate the Pharmacodynamics and Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants With Mutations Amenable to Exon 44 Skipping
Study identification
- NCT ID
- NCT06244082
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Avidity Biosciences, Inc.
- Industry
- Enrollment
- 39 participants
Conditions and interventions
Conditions
Interventions
- AOC 1044 Drug
Drug
Eligibility (public fields only)
- Age range
- 7 Years to 27 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 21, 2024
- Primary completion
- Apr 29, 2027
- Completion
- Jul 30, 2027
- Last update posted
- May 13, 2025
2024 – 2027
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arkansas Children's Hospital | Little Rock | Arkansas | 72202 | — |
| University of California, San Diego, Rady's Children's Hospital | La Jolla | California | 92037 | — |
| UC Davis Medical Center | Sacramento | California | 95817 | — |
| Lucille Packard Children's Hospital at Stanford | San Carlos | California | 94070 | — |
| Rare Disease Research - Atlanta | Atlanta | Georgia | 30329 | — |
| University of Massachusetts Medical School | Worcester | Massachusetts | 01655 | — |
| Gillette Children's Specialty Healthcare | Saint Paul | Minnesota | 55101 | — |
| Rare Disease Research | Hillsborough | North Carolina | 27278 | — |
| Abigail Wexner Research Institute at Nationwide Children's Hospital | Columbus | Ohio | 43215 | — |
| Neurology Rare Disease Center | Denton | Texas | 76208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06244082, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 13, 2025 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06244082 live on ClinicalTrials.gov.